According to Mukherjee et al.’s study, in NSCLC with constitutive IL6–STAT3 activation for uncontrolled cell proliferation, targeted blockade of NF-κB and IL-6–STAT3 signaling by quercetin (66 μM of quercetin for 12, 18, 24, 36, and 48 h) represents an innovative approach for treating NSCLC. This evidence concerns the gene IL6 and non-small cell lung carcinoma.